Tacrine therapy is associated with reduced mortality in nursing home residents with dementia

Journal of the American Geriatrics Society

Volumn 50, Issue 1, 2002, Pages 35-40

  Ott, Brian R ^a,b,c   Lapane, Kate L ^b  

^a BROWN UNIVERSITY   (United States)

^b BROWN UNIVERSITY   (United States)

^c MEMORIAL HOSPITAL OF RHODE ISLAND   (United States)

Author keywords

Cognitive disorders; Dementia; Epidemiology

Indexed keywords

TACRINE;

AGED; ARTICLE; COGNITION; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEMENTIA; DISEASE SEVERITY; FEMALE; HEALTH CARE FACILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NURSING HOME; QUALITY OF LIFE; RETROSPECTIVE STUDY; SOCIOECONOMICS; STATISTICAL MODEL; SURVIVAL RATE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; COHORT STUDIES; COMORBIDITY; DEMENTIA; FEMALE; HUMANS; MALE; NURSING HOMES; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TACRINE; UNITED STATES;

EID: 0036143649     PISSN: 00028614     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1532-5415.2002.50005.x     Document Type: Article

References (42)

1. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease
2. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomized controlled trial
3. The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients
4. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease
5. Donepezil preserves activities of daily living in Alzheimer's disease patients: Results from a one-year placebo-controlled functional survival study
6. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension
7. A 5-month, randomized, placebocontrolled trial of galantamine in AD
8. Effect of tacrine on behavioral symptoms in Alzheimer's disease: An open-label study
9. Beyond the cholinergic hypothesis: The effect of metrifonate and other cholinesterase inhibitors on neuropsychiatric symptoms in Alzheimer's disease
10. Effect of tacrine on language, praxis, and noncognitive behavioral problems in Alzheimer disease
11. Rivastigmine provides symptomatic benefit in dementia with lewy bodies: Findings from a placebo-controlled international multicenter study
12. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: An interim analysis of the results of a U.S. multicentre open label extension study
13. Long-term tacrine (Cognex) treatment: Effects on nursing home placement and mortality
14. Letter
15. Letter
16. Participation in clinical trials and long term outcomes in Alzheimer's disease
17. The economic impact of tacrine in the treatment of Alzheimer's disease
18. Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada
19. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease
20. Treatment of Alzheimer disease with tacrine: A cost-analysis model
21. Tacrine use in nursing homes: Implications for prescribing new cholinesterase inhibitors
22. Case reports: Donepezil in the treatment of advanced Alzheimer's disease
23. The SAGE database: Introducing functional outcomes in geriatric pharmaco-epidemiology
24. Characteristics of the SAGE database: A new resource for research on outcomes in long-term care
25. Designing the national resident assessment instrument for nursing homes
26. Validity of diagnostic and drug data in standardized nursing home resident assessments: Ppotential for geriatric pharmacoepidemiology
27. Gender differences in the treatment of behavior problems in Alzheimer's disease
28. MDS cognitive performance scale
29. The structure of social engagement among nursing home residents
30. The MDS cognition scale: A valid instrument for identifying and staging nursing home residents with dementia using the minimum data set
31. Validation of the Minimum Data Set Cognitive Performance Scale: Agreement with the Mini Mental State Examination
32. Reliability estimates for the Minimum Data Set for nursing home resident assessment and care screening (MDS)
33. Research evaluation and diagnosis of possible Alzheimer's disease over the last two decades: II
34. Validity of the Minimum Data Set for assessing nutritional status in nursing home residents
35. CERAD. Part XIV: Demographic and clinical predictors of survival in patients with Alzheimer's disease
36. Neurological and psychiatric predictors of mortality inpatients with Alzheimer disease in California
37. Comorbidity and drug use in cognitively impaired elderly living in long-term care
38. Psychiatric medication and abnormal behavior as predictors of progression in probable Alzheimer disease
39. Gender differences in the relation between comorbidity and mortality of patients with Alzheimer's disease
40. A controlled trial of tacrine in Alzheimer's disease